| Aug 12 |
Crown Laboratories to buy Revance Therapeutics for $6.66/share in cash
|
| Aug 12 |
Botox rival maker Revance to go private in $924 million deal
|
| Aug 12 |
Crown Laboratories and Revance Announce Entry Into Merger Agreement
|
| Aug 9 |
Revance Therapeutics, Inc. (RVNC) Q2 2024 Earnings Call Transcript
|
| Aug 8 |
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Misses Revenue Estimates
|
| Aug 8 |
Revance Therapeutics GAAP EPS of -$0.36 beats by $0.12, revenue of $65.3M misses by $0.99M
|
| Aug 8 |
Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update
|
| Aug 7 |
Revance Therapeutics Q2 2024 Earnings Preview
|
| Aug 1 |
Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
|
| Jul 11 |
Stocks to Buy: 3 Breakout Stars to Transform Your Portfolio
|
